CAMP4 Therapeutics (NASDAQ:CAMP) Stock Rating Raised to Hold at Wall Street Zen

CAMP4 Therapeutics (NASDAQ:CAMP) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

A number of other research firms have also recently commented on CAMP. Weiss Ratings raised CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 16th. Needham & Company LLC initiated coverage on CAMP4 Therapeutics in a research note on Thursday, October 15th. They issued a “buy” rating and a $8.00 price target on the stock. UBS Group set a $15.00 target price on shares of CAMP4 Therapeutics in a report on Friday, August 14th. Raymond James Financial assumed coverage on CAMP4 Therapeutics in a research report on Friday, October 23rd. They set a “strong-buy” rating and a $10.00 price target on the stock. Finally, Oppenheimer started coverage on shares of CAMP4 Therapeutics in a report on Monday, October 5th. They set an “outperform” rating and a $15.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, CAMP4 Therapeutics has an average rating of “Moderate Buy” and an average price target of $10.44.

CAMP4 Therapeutics Stock Performance

Shares of CAMP4 Therapeutics stock opened at $4.06 on Friday. The company has a market cap of $254.76 million, a P/E ratio of -1.90 and a beta of 0.28. The firm has a fifty day moving average of $3.84 and a two-hundred day moving average of $4.20. CAMP4 Therapeutics has a one year low of $2.90 and a one year high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last posted its quarterly earnings data on Thursday, November 5th. The Wireless communications provider reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.17). The firm had revenue of $1.90 million for the quarter. CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%. As a group, equities analysts predict that CAMP4 Therapeutics will post -0.68 earnings per share for the current year.

Insider Activity at CAMP4 Therapeutics

In other CAMP4 Therapeutics news, CFO Kelly Gold acquired 10,000 shares of the stock in a transaction that occurred on Monday, August 31st. The stock was bought at an average cost of $3.96 per share, for a total transaction of $39,600.00. Following the completion of the transaction, the chief financial officer owned 10,000 shares of the company’s stock, valued at approximately $39,600. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Andrew Schwab sold 400,000 shares of CAMP4 Therapeutics stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $4.04, for a total transaction of $1,616,000.00. Following the completion of the transaction, the director directly owned 2,033,270 shares in the company, valued at $8,214,410.80. The trade was a 16.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 593,613 shares of company stock valued at $2,504,037. Corporate insiders own 21.69% of the company’s stock.

Hedge Funds Weigh In On CAMP4 Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jupiter Topco LLC purchased a new position in CAMP4 Therapeutics in the second quarter worth $27,581,000. 5AM Venture Management LLC bought a new position in CAMP4 Therapeutics in the second quarter worth approximately $25,647,928. Trails Edge Capital Partners LP purchased a new position in shares of CAMP4 Therapeutics during the 2nd quarter valued at about $8,446,935. BlackRock Inc. acquired a new position in CAMP4 Therapeutics during the second quarter worth $7,185,000. Finally, SummitTX Capital L.P. acquired a new position in CAMP4 Therapeutics during the 1st quarter worth $1,497,000.

CAMP4 Therapeutics Company Profile

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing medicines that increase the production of disease-relevant proteins by activating the expression of specific genes. The company’s approach is designed to address diseases caused by insufficient protein levels, including certain genetic disorders in which boosting activity from a functional gene copy may provide therapeutic benefit.

CAMP4 uses its Regulatory Action Platform, or RAP, to identify regulatory elements that control RNA production and discover small-molecule compounds capable of increasing the expression of selected genes.